{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T23:31:24Z","timestamp":1782948684286,"version":"3.54.5"},"reference-count":33,"publisher":"Japan Endocrine Society","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2024]]},"DOI":"10.1507\/endocrj.ej23-0729","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T22:12:56Z","timestamp":1718230376000},"page":"851-861","source":"Crossref","is-referenced-by-count":2,"title":["Therapeutic effect of selective interleukin-2-inducible tyrosine kinase inhibitor in orbital fibroblasts from patients with Graves\u2019 orbitopathy"],"prefix":"10.1507","volume":"71","author":[{"given":"Yeonjung","family":"Yoon","sequence":"first","affiliation":[{"name":"The Institute of Vision Research, Department of Ophthalmology, Yonsei University College of Medicine, Seoul 03722, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Young","family":"Park","sequence":"additional","affiliation":[{"name":"The Institute of Vision Research, Department of Ophthalmology, Yonsei University College of Medicine, Seoul 03722, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Kyung","family":"Chae","sequence":"additional","affiliation":[{"name":"The Institute of Vision Research, Department of Ophthalmology, Yonsei University College of Medicine, Seoul 03722, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Young","family":"Jang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon 14584, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Sook","family":"Yoon","sequence":"additional","affiliation":[{"name":"The Institute of Vision Research, Department of Ophthalmology, Yonsei University College of Medicine, Seoul 03722, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Hiromatsu Y, Eguchi H, Tani J, Kasaoka M, Teshima Y (2014) Graves\u2019 ophthalmopathy: epidemiology and natural history. Intern Med 53: 353\u2013360.","DOI":"10.2169\/internalmedicine.53.1518"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Huang Y, Fang S, Li D, Zhou H, Li B, et al. (2019) The involvement of T cell pathogenesis in thyroid-associated ophthalmopathy. Eye (Lond) 33: 176\u2013182.","DOI":"10.1038\/s41433-018-0279-9"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Smith TJ, Heged\u00fcs L, Douglas RS (2012) Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves\u2019 orbitopathy. Best Pract Res Clin Endocrinol Metab 26: 291\u2013302.","DOI":"10.1016\/j.beem.2011.10.002"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Zhang L, Baker G, Janus D, Paddon CA, Fuhrer D, et al. (2006) Biological effects of thyrotropin receptor activation on human orbital preadipocytes. Invest Ophthalmol Vis Sci 47: 5197\u20135203.","DOI":"10.1167\/iovs.06-0596"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Smith TJ, Bahn RS, Gorman CA (1989) Connective tissue, glycosaminoglycans, and diseases of the thyroid. Endocr Rev 10: 366\u2013391.","DOI":"10.1210\/edrv-10-3-366"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Taylor PN, Zhang L, Lee RWJ, Muller I, Ezra DG, et al. (2020) New insights into the pathogenesis and nonsurgical management of Graves orbitopathy. Nat Rev Endocrinol 16: 104\u2013116.","DOI":"10.1038\/s41574-019-0305-4"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Rivera-Grana E, Lin P, Suhler EB, Rosenbaum JT (2015) Methotrexate as a corticosteroid-sparing agent for thyroid eye disease. J Clin Exp Ophthalmol 6: 422.","DOI":"10.4172\/2155-9570.1000422"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Kahaly G, Schrezenmeir J, Krause U, Schweikert B, Meuer S, et al. (1986) Ciclosporin and prednisone v. prednisone in treatment of Graves\u2019 ophthalmopathy: a controlled, randomized and prospective study. Eur J Clin Investig 16: 415\u2013422.","DOI":"10.1111\/j.1365-2362.1986.tb01016.x"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Perros P, Weightman DR, Crombie AL, Kendall-Taylor P (1990) Azathioprine in the treatment of thyroid-associated ophthalmopathy. Acta Endocrinol (Copenh) 122: 8\u201312.","DOI":"10.1530\/acta.0.1220008"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Shen WC, Lee CH, Loh EW, Hsieh AT, Chen L, et al. (2018) Efficacy and safety of rituximab for the treatment of Graves\u2019 orbitopathy: a meta-analysis of randomized controlled trials. Pharmacotherapy 38: 503\u2013510.","DOI":"10.1002\/phar.2111"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Ting M, Ezra DG (2020) Teprotumumab: a disease modifying treatment for Graves\u2019 orbitopathy. Thyroid Res 13: 12.","DOI":"10.1186\/s13044-020-00086-7"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Qi Q, Huang W, Bai Y, Balmus G, Weiss RS, et al. (2012) A unique role for ITK in survival of invariant NKT cells associated with the p53-dependent pathway in mice. J Immunol 188: 3611\u20133619.","DOI":"10.4049\/jimmunol.1102475"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Sahu N, August A (2009) ITK inhibitors in inflammation and immune-mediated disorders. Curr Top Med Chem 9: 690\u2013703.","DOI":"10.2174\/156802609789044443"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Das J, Liu C, Moquin RV, Lin J, Furch JA, et al. (2006) Discovery and SAR of 2-amino-5-[(thiomethyl)aryl]thiazoles as potent and selective ITK inhibitors. Bioorg Med Chem Lett 16: 2411\u20132415.","DOI":"10.1016\/j.bmcl.2006.01.115"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15 Lin TA, McIntyre KW, Das J, Liu C, O\u2019Day KD, et al. (2004) Selective ITK inhibitors block T-cell activation and murine lung inflammation. Biochemistry 43: 11056\u201311062.","DOI":"10.1021\/bi049428r"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Yoon JS, Lee HJ, Choi SH, Chang EJ, Lee SY, et al. (2011) Quercetin inhibits IL-1\u03b2-induced inflammation, hyaluronan production and adipogenesis in orbital fibroblasts from Graves\u2019 orbitopathy. PLoS One 6: e26261.","DOI":"10.1371\/journal.pone.0026261"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Lechner KS, Neurath MF, Weigmann B (2020) Role of the IL-2 inducible tyrosine kinase ITK and its inhibitors in disease pathogenesis. J Mol Med (Berl) 98: 1385\u20131395.","DOI":"10.1007\/s00109-020-01958-z"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Fowell DJ, Shinkai K, Liao XC, Beebe AM, Coffman RL, et al. (1999) Impaired NFATc translocation and failure of Th2 development in ITK-deficient CD4+ T cells. Immunity 11: 399\u2013409.","DOI":"10.1016\/S1074-7613(00)80115-6"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Gomez-Rodriguez J, Meylan F, Handon R, Hayes ET, Anderson SM, et al. (2016) Itk is required for Th9 differentiation <i>via<\/i> TCR-mediated induction of IL-2 and IRF4. Nat Commun 7: 10857.","DOI":"10.1038\/ncomms10857"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Andreotti AH, Schwartzberg PL, Joseph RE, Berg LJ (2010) T-cell signaling regulated by the Tec family kinase, ITK. Cold Spring Harb Perspect Biol 2: a002287.","DOI":"10.1101\/cshperspect.a002287"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Gomez-Rodriguez J, Kraus ZJ, Schwartzberg PL (2011) Tec family kinases ITK and Rlk \/ Txk in T lymphocytes: cross-regulation of cytokine production and T-cell fates. FEBS J 278: 1980\u20131989.","DOI":"10.1111\/j.1742-4658.2011.08072.x"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Liu X, Berry CT, Ruthel G, Madara JJ, MacGillivray K, et al. (2016) T cell receptor-induced nuclear factor kappaB (NF-kappaB) signaling and transcriptional activation are regulated by STIM1- and Orai1-mediated calcium entry. J Biol Chem 291: 8440\u20138452.","DOI":"10.1074\/jbc.M115.713008"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Matsumoto Y, Oshida T, Obayashi I, Imai Y, Matsui K, et al. (2002) Identification of highly expressed genes in peripheral blood T cells from patients with atopic dermatitis. Int Arch Allergy Immunol 129: 327\u2013340.","DOI":"10.1159\/000067589"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 von Bonin A, Rausch A, Mengel A, Hitchcock M, Kr\u00fcger M, et al. (2011) Inhibition of the IL-2-inducible tyrosine kinase (Itk) activity: a new concept for the therapy of inflammatory skin diseases. Exp Dermatol 20: 41\u201347.","DOI":"10.1111\/j.1600-0625.2010.01198.x"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Cho HS, Shin HM, Haberstock-Debic H, Xing Y, Owens TD, et al. (2015) A small molecule inhibitor of ITK and RLK impairs Th1 differentiation and prevents colitis disease progression. J Immunol 195: 4822\u20134831.","DOI":"10.4049\/jimmunol.1501828"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Kannan AK, Kim DG, August A, Bynoe MS (2015) ITK signals promote neuroinflammation by regulating CD4+ T-cell activation and trafficking. J Neurosci 35: 221\u2013233.","DOI":"10.1523\/JNEUROSCI.1957-14.2015"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Lo HY (2010) ITK inhibitors: a patent review. Expert Opin Ther Pat 20: 459\u2013469.","DOI":"10.1517\/13543771003674409"},{"key":"28","doi-asserted-by":"publisher","unstructured":"28 Dubovsky JA, Beckwith KA, Natarajan G, Woyach JA, Jaglowski S, et al. (2013) Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood 122: 2539\u20132549.","DOI":"10.1182\/blood-2013-06-507947"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Zhong Y, Dong S, Strattan E, Ren L, Butchar JP, et al. (2015) Targeting interleukin-2-inducible T-cell kinase (ITK) and resting lymphocyte kinase (RLK) using a novel covalent inhibitor PRN694. J Biol Chem 290: 5960\u20135978.","DOI":"10.1074\/jbc.M114.614891"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Otake S, Otsubaki T, Uesato N, Ueda Y, Murayama T, et al. (2021) Topical application of BMS-509744, a selective Inhibitor of interleukin-2-inducible T cell kinase, ameliorates imiquimod-induced skin inflammation in mice. Biol Pharm Bull 44: 528\u2013534.","DOI":"10.1248\/bpb.b20-00850"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Gu LQ, Jia HY, Zhao YJ, Liu N, Wang S, et al. (2009) Association studies of interleukin-8 gene in Graves\u2019 disease and Graves\u2019 ophthalmopathy. Endocrine 36: 452\u2013456.","DOI":"10.1007\/s12020-009-9240-9"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Kim SE, Yoon JS, Kim KH, Lee SY (2012) Increased serum interleukin-17 in Graves\u2019 ophthalmopathy. Graefes Arch Clin Exp Ophthalmol 250: 1521\u20131526.","DOI":"10.1007\/s00417-012-2092-7"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Chen H, Mester T, Raychaudhuri N, Kauh CY, Gupta S, et al. (2014) Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes. J Clin Endocrinol Metab 99: E1635\u2013E1640.","DOI":"10.1210\/jc.2014-1580"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/71\/9\/71_EJ23-0729\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T04:12:19Z","timestamp":1725682339000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/71\/9\/71_EJ23-0729\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej23-0729","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]},"article-number":"EJ23-0729"}}